Skip to main content

Advertisement

SpringerLink
Log in

The prevalence and clinical correlates of metabolic syndrome in patients with schizophrenia: findings from a cohort in Turkey

  • Original Paper
  • Published:
European Archives of Psychiatry and Clinical Neuroscience Aims and scope Submit manuscript

An Erratum to this article was published on 27 November 2010

Abstract

Most studies point to an increased prevalence of metabolic syndrome (MS) and an increased risk of coronary heart disease (CHD) in schizophrenia patients with MS. The aims of this study were to compare the prevalence of MS in schizophrenia patients with the general population, to explore the clinical correlates and predictors of MS and to evaluate the risk for CHD within 10 years. Consecutive 319 patients, aged 18–75 years, with a diagnosis of schizophrenia according to the DSM-IV were enrolled. The ATP-III, the ATP-IIIA and the IDF criteria were used to define MS. 10-year risk of CHD events was calculated with the Framingham score. One hundred nine (34.2%) patients met the ATP-III criteria, 118 (37%) the ATP-IIIA and 133 (41.7%) the IDF criteria for MS. Patients with MS were older, had a later onset of illness and an older age at first hospitalization. The prevalence of MS in schizophrenia patients was higher from the general population only within the 20–29 age group. Patients with MS had a higher age and sex-corrected 10-year risk of CHD events. The only predictor of MS was the age of illness onset. In conclusion, countries where the general population prevalence of MS is already too high, schizophrenia patients younger than 30 years of age might be under higher risk of morbidity and mortality related with MS. This study points to the necessity for aggressive interventions to correct MS in schizophrenia as early as possible, within the first 10 years of post detection.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (2001) Executive summary of the third report of the National Cholesterol education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285:2486–2497

    Article  Google Scholar 

  2. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (2003) Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 26:3160–3166

    Article  Google Scholar 

  3. Grundy SM, Brewer B, Cleeman JL, Smith SC, Lenfant C (2004) Definition of metabolic syndrome: report of the National Heart, Lung, And Blood Institute/American Heart Association Conference on scientific issues related to definition. Circulation 109:433–438

    Article  PubMed  Google Scholar 

  4. IDF (2005) The IDF Consensus Worldwide Definition of the Metabolic Syndrome. International Diabetes Federation, Brussels

    Google Scholar 

  5. Suvisaari J, Perälä J, Saarni SI, Härkänen T, Pirkola S, Joukamaa M, Koskinen S, Lönnqvist J, Reunanen A (2008) Type 2 diabetes among persons with schizophrenia and other psychotic disorders in a general population survey. Eur Arch Psychiatry Clin Neurosci 258:129–136

    Article  PubMed  Google Scholar 

  6. Barnett AH, Millar HL, Loze JY, L’Italien GJ, van Baardewijk M, Knapp M (2009) UK cost-consequence analysis of aripiprazole in schizophrenia: diabetes and coronary heart disease risk projections (STAR study). Eur Arch Psychiatry Clin Neurosci 259:239–247

    Article  PubMed  Google Scholar 

  7. Leucht S (2009) Physical illness and schizophrenia. Eur Arch Psychiatry Clin Neurosci 259(Suppl 1):S34

    Google Scholar 

  8. Heiskanen T, Niskanen L, Lyytikainen R, Saarinen PI, Hintikka J (2003) Metabolic syndrome in patients with schizophrenia. J Clin Psychiatry 64:575–579

    Article  PubMed  Google Scholar 

  9. Littrell KH, Petty R, Ortega TR, Moore D, Ballard A, Clough R, Lan TS, Selby C (2003) Insulin resistance and Syndrome X among patients with schizophrenia. Abstract presented at the American Psychiatric Association Annual Meeting, San Francisco

  10. Kato MM, Currier MB, Gomez CM, Hall L, Gonzalez-Blanco M (2004) Prevalence of metabolic syndrome in Hispanic and non-Hispanic patients with schizophrenia. Prim Care Companion J Clin Psychiatry 6:74–77

    Article  PubMed  Google Scholar 

  11. Basu R, Brar JS, Chengappa KNR, John V, Parapally H, Gershon S, Schlicht P, Kupfer D (2004) The prevalence of the metabolic syndrome in patients with schizoaffective disorder-bipolar subtype. Bipolar Disord 6:314–318

    Article  PubMed  Google Scholar 

  12. Cohn T, Prud’homme D, Streiner D, Kameh H, Remington G (2004) Characterizing coronary heart disease risk in schizophrenia: high prevalence of the metabolic syndrome. Can J Psychiatry 49:753–760

    PubMed  Google Scholar 

  13. Meyer JM, Pandina G, Bossie CA, Turkoz I, Greenspan A (2005) Effects of switching from olanzapine to risperidone on the prevalence of the metabolic syndrome in overweight or obese patients with schizophrenia or schizoaffective disorder: analysis of a multicenter, rater-blinded, open-label study. Clin Ther 27:1930–1941

    Article  CAS  PubMed  Google Scholar 

  14. Saari KM, Lindeman SM, Viilo KM, Isohanni MK, Jarvelin M-R, Lauren LH, Savolainen MJ, Koponen HJ (2005) A 4-fold risk of metabolic syndrome in patients with schizophrenia: the northern Finland 1966 birth cohort study. J Clin Psychiatry 66:559–563

    Article  PubMed  Google Scholar 

  15. Koponen HJ, Hakko HH, Saari KM, Lindeman SM, Karvonen KM, Isohanni MK, Lauren LH, Savolainen MJ, Jarvelin MR (2008) The prevalence and predictive value of individual criteria for metabolic syndrome in schizophrenia: a Northern Finland 1966 Birth Cohort Study. World J Biol Psychiatry 1–6

  16. McEvoy JP, Meyer JM, Goff DC, Nasrallah HA, Davis SM, Sullivan L, Meltzer HY, Hsiao J, Stroup TS, Lieberman JA (2005) Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the clinical antipsychotic trial and comparison with national estimates from NHANES III. Schizophr Res 80:19–32

    Article  PubMed  Google Scholar 

  17. Hagg S, Lindblom Y, Mjorndal T, Adolfsson R (2006) High prevalence of the metabolic syndrome among a Swedish cohort of patients with schizophrenia. Int Clin Psychopharmacol 21:93–98

    Article  PubMed  Google Scholar 

  18. Meyer JM, Loh C, Leckband SG, Boyd JA, Wirshing WC, Pierre JM, Wirshing D (2006) Prevalence of the metabolic syndrome in veterans with schizophrenia. J Psychiatr Pract 12:5–10

    Article  PubMed  Google Scholar 

  19. Correll CU, Frederickson AM, Kane JM, Manu P (2006) Metabolic syndrome and the risk of coronary heart disease in 367 patients treated with second-generation antipsychotic drugs. J Clin Psychiatry 67:575–583

    Article  CAS  PubMed  Google Scholar 

  20. Lamberti JS, Olson D, Crilly JF, Olivares T, Williams GC, Tu X, Tang W, Wiener K, Dvorin S, Dietz MB (2006) Prevalence of the metabolic syndrome among patients receiving clozapine. Am J Psychiatry 163:1273–1276

    Article  PubMed  Google Scholar 

  21. De Hert M, van Winkel R, Van Eyck D, Hanssens L, Wampers M, Scheen A, Peuskens J (2006) Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication. Schizophr Res 83:87–93

    Article  PubMed  Google Scholar 

  22. Teixeira PJ, Rocha FL (2007) The prevalence of metabolic syndrome among psychiatric inpatients in Brazil. Rev Bras Psiquiatr 29:330–336

    Article  PubMed  Google Scholar 

  23. Sanchez-Arana Moreno T, Tourino Gonzalez R, Hernandez Fleta JL, Leon Perez P (2007) Prevalence of the metabolic syndrome among schizophrenic patients hospitalized in the Canary Islands. Actas Esp Psiquiatr 35:359–367

    CAS  PubMed  Google Scholar 

  24. Tirupati S, Chua LE (2007) Body mass index as a screening test for metabolic syndrome in schizophrenia and schizoaffective disorders. Australas Psychiatry 15:470–473

    Article  PubMed  Google Scholar 

  25. Srisurapanont M, Likhitsathian S, Boonyanaruthee V, Charnsilp C, Jarusuraisin N (2007) Metabolic syndrome in Thai schizophrenic patients: a naturalistic one-year follow-up study. BMC Psychiatry 7:14

    Google Scholar 

  26. Kurt E, Altinbas K, Alatas G, Ozver İ (2007) Metabolic syndrome prevalence among schizophrenic patients treated in chronic inpatient clinics. Psychiatry in Türkiye 3:141–145

    Google Scholar 

  27. Bobes J, Arango C, Aranda P, Carmena R, Garcia-Garcia M, Rejas J, Study Collaborative Group CLAMORS (2007) Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: results of the CLAMORS study. Schizophr Res 90:162–173

    Article  PubMed  Google Scholar 

  28. Rejas J, Bobes J, Arango C, Aranda P, Carmena R, Garcia-Garcia M (2008) Concordance of standard and modified NCEP ATP III criteria for identification of metabolic syndrome in outpatients with schizophrenia treated with antipsychotics: a corollary from the CLAMORS study. Schizophr Res 99:23–28, 26

    Google Scholar 

  29. Saddichha S, Manjunatha N, Ameen S, Akhtar S (2008) Metabolic syndrome in first episode schizophrenia—a randomized double-blind controlled, short-term prospective study. Schizophr Res 101:266–272

    Article  PubMed  Google Scholar 

  30. Correll CU, Frederickson AM, Kane JM, Manu P (2008) Equally increased risk for metabolic syndrome in patients with bipolar disorder and schizophrenia treated with second-generation antipsychotics. Bipolar Disord 10:788–797

    Article  PubMed  Google Scholar 

  31. Cerit C, Ozten E, Yildiz M (2008) The prevalence of metabolic syndrome and related factors in patients with schizophrenia. Turk Psikiyatri Derg 19:124–132

    PubMed  Google Scholar 

  32. Boke O, Aker S, Sarisoy G, Saricicek EB, Sahin AR (2008) Prevalence of metabolic syndrome among inpatients with schizophrenia. Int J Psychiatry Med 38:103–112

    Article  PubMed  Google Scholar 

  33. Oyekcin DG (2009) The frequency of metabolic syndrome in patients with schizophrenia and schizoaffective disorder. Anatolian J Psychiatry 10:26–33

    Google Scholar 

  34. Kaya MC, Virit O, Altındağ A, Selek S, Bülbül F, Bulut M, Savaş HA (2009) Prevalence of metabolic syndrome, characteristics of metabolic syndrome and relationship with the antipsychotics used in schizophrenia. Arch Neuropsychiatry 46:13–18

    Google Scholar 

  35. Brunero S, Lamont S, Fairbrother G (2009) Prevalence and predictors of metabolic syndrome among patients attending an outpatient clozapine clinic in Australia. Arch Psychiatr Nurs 23:261–268

    Article  PubMed  Google Scholar 

  36. Huang MC, Lu ML, Tsai CJ, Chen PY, Chiu CC, Jian DL, Lin KM, Chen CH (2009) Prevalence of metabolic syndrome among patients with schizophrenia or schizoaffective disorder in Taiwan. Acta Psychiatr Scand 120:274–280

    Article  PubMed  Google Scholar 

  37. Goff DC, Sullivan LM, McEvoy JP, Meyer JM, Nasrallah HA, Daumit GL, Lamberti S, D’Agastino RB, Stroup TS, Davis S, Lieberman JA (2005) A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophr Res 80:45–53

    Article  PubMed  Google Scholar 

  38. Arango C, Bobes J, Aranda P, Carmena R, Garcia-Garcia M, Rejas J; on behalf of the CLAMORS study collaborative group (2008) A comparison of schizophrenia outpatients treated with antipsychotics with and without metabolic syndrome: findings from the CLAMORS study. Schizophr Res 104:1–12

    Google Scholar 

  39. Kozan O, Oguz A, Abaci A, Erol C, Ongen Z, Temizhan A, Celik S (2007) Prevalence of the metabolic syndrome among Turkish adults. Eur J Clin Nutr 61:548–553

    CAS  PubMed  Google Scholar 

  40. Wilson PW, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB (1998) Prediction of coronary heart disease using risk factor categories. Circulation 97:1837–1847

    CAS  PubMed  Google Scholar 

  41. Onat A, Sansoy V (2002) Metabolic syndrome, major culprit of coronary disease among Turks: its prevalence and impact on coronary risk. Türk Kardiyol Dern Arş 30:8–15

    Google Scholar 

  42. Straker D, Correll CU, Kramer-Ginsberg E, Abdulhamid N, Koshy F, Rubens E, Saint-Vil R, Kane JM, Manu P (2005) Cost-effective screening for the metabolic syndrome in patients treated with second-generation antipsychotic medications. Am J Psychiatry 162:1217–1221

    Article  PubMed  Google Scholar 

  43. De Hert M, Schreurs V, Vancampfort D, Van Winkel RD (2009) Metabolic syndrome in people with schizophrenia: a review. World Psychiatry 8:15–22

    Google Scholar 

  44. De Hert M, Dekker JM, Wood D, Kahl KG, Holt RIG, Möller HJ (2009) Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). Eur Psychiatry 24:412–424

    Article  PubMed  Google Scholar 

  45. Haupt DW (2006) Differential metabolic effects of antipsychotic treatments. Eur Neuropsychopharmacol 16:S149–S155

    Article  CAS  PubMed  Google Scholar 

  46. De Hert M, Schreurs V, Sweers K, Van Eyck D, Hanssens L, Sinko S, Wampers M, Scheen A, Peuskens J, van Winkel R (2008) Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: a retrospective chart review. Schizophr Res 101:295–303

    Article  PubMed  Google Scholar 

  47. Meyer JM, Davis VG, Goff DC, McEvoy JP, Nasrallah HA, Davis SM, Rosenheck RA, Daumit GL, Hsiao J, Swartz MS, Stroup TS, Lieberman JA (2008) Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1. Schizophr Res 101:273–286

    Article  PubMed  Google Scholar 

  48. Stahl SM, Mignon L, Meyer JM (2009) Which comes first: atypical antipsychotics treatment or cardiometabolic risk? Acta Psychiatr Scand 119:171–179

    Article  CAS  PubMed  Google Scholar 

  49. Simon V, van Winkel R, De Hert M (2009) Are weight gain and metabolic side effects of atypical antipsychotics dose dependent? A literature review. J Clin Psychiatry 70:1041–1050

    Article  CAS  PubMed  Google Scholar 

  50. Bermudes RA, Keck PE Jr, Welge JA (2006) The prevalence of the metabolic syndrome in psychiatric inpatients with primary psychotic and mood disorders. Psychosomatics 47:491–497

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

We thank Professor Sanjay Gupta MD for his contribution to the study design.

Author information

Authors and Affiliations

  1. Department of Psychiatry, Hacettepe University Faculty of Medicine, 06100, Ankara, Turkey

    M. K. Yazıcı, A. E. Anıl Yağcıoğlu, A. Ertuğrul & N. Eni

  2. Department of Biostatistics, Hacettepe University Faculty of Medicine, 06100, Ankara, Turkey

    S. Karahan & E. Karaağaoğlu

  3. Department of Cardiology, Hacettepe University Faculty of Medicine, 06100, Ankara, Turkey

    S. L. Tokgözoğlu

Authors
  1. M. K. Yazıcı
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. E. Anıl Yağcıoğlu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. Ertuğrul
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. N. Eni
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S. Karahan
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. E. Karaağaoğlu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. S. L. Tokgözoğlu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. K. Yazıcı.

Additional information

An erratum to this article can be found at http://dx.doi.org/10.1007/s00406-010-0171-5

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yazıcı, M.K., Anıl Yağcıoğlu, A.E., Ertuğrul, A. et al. The prevalence and clinical correlates of metabolic syndrome in patients with schizophrenia: findings from a cohort in Turkey. Eur Arch Psychiatry Clin Neurosci 261, 69–78 (2011). https://doi.org/10.1007/s00406-010-0118-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00406-010-0118-x

Keywords

Search

Navigation